Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade A 137.38 4.02% 5.31
ARGX closed up 4.02 percent on Friday, May 24, 2019, on 3.27 times normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARGX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 4.02%
50 DMA Support Bullish 4.02%

Older signals for ARGX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Immunotherapy Solid Tumors Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Treatment Of Hematological Cancers Tolerx
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 137.5
52 Week Low 63.81
Average Volume 164,724
200-Day Moving Average 104.4663
50-Day Moving Average 126.0518
20-Day Moving Average 126.092
10-Day Moving Average 127.998
Average True Range 4.9634
ADX 14.63
+DI 30.8185
-DI 21.383
Chandelier Exit (Long, 3 ATRs ) 122.6098
Chandelier Exit (Short, 3 ATRs ) 128.7102
Upper Bollinger Band 136.1032
Lower Bollinger Band 116.0808
Percent B (%b) 1.06
BandWidth 15.879199
MACD Line 2.2184
MACD Signal Line 0.8325
MACD Histogram 1.3859
Fundamentals Value
Market Cap 3.69 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -108.17
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 144.42
Resistance 3 (R3) 143.67 140.59 143.24
Resistance 2 (R2) 140.59 138.80 140.96 142.85
Resistance 1 (R1) 138.98 137.69 139.79 139.73 142.46
Pivot Point 135.90 135.90 136.30 136.27 135.90
Support 1 (S1) 134.29 134.11 135.10 135.04 132.30
Support 2 (S2) 131.21 133.00 131.58 131.91
Support 3 (S3) 129.60 131.21 131.52
Support 4 (S4) 130.35